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The distributions of medical costs are often skewed to the right because small numbers of patients use large
amounts of health care resources. Using data from a study of colon cancer costs, we show, by example, the impact
and magnitude of outliers and influential observations on health care costs and compared the effects of statistical
costing methods for addressing the disproportionate influence of outliers and influential observations. We used
data from a retrospective cohort study of 3,842 elderly veterans with colon cancer who were enrolled in and used
health care from, both the Department of Veterans Affairs and Medicare in 1999–2004. After calculating the average
colon cancer episode cost and distribution for the full cohort, we used box-plot methods, Winsorization, DFBETAs,
and Cook's distance to identify and assess or adjust the outlying and/or influential observations. The number of
observations identified as outlying and/or influential ranged from 13 when the predicted DFBETA measurement
was greater than 0.15 and the observation was a qualified box-plot outlier to 384 cases using the Winsorization
method at the 5th and 95th percentiles. Average costs of colon cancer episodes using these methods were similar.
The method of choice from the results of this particular analysis can be conditionally based on whether the
purpose is to control only for influential observations or to simultaneously control for outliers and influential
observations. Understanding how estimates could change with each approach is important in assessing the impact
of a particular method on the results.
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Determining the costs of episodes of medical care is an im-
portant step in making policy decisions about allocating
health care resources. However, as has been well docu-
mented in the literature, accurately estimating costs is chal-
lenging due to right skewing when small numbers of
patients use larger amounts of health care resources than
most other patients (Mullahy 1998). In 2009, for example,
22% of total health care expenditures in the United States
were allocated to just 1% of the U.S. population, and almost
50% of health care spending was devoted to 5% of the
population (Cohen and Yu 2012). In addition, no single es-
timator is appropriate for all of the processes typically used* Correspondence: Denise.Hynes@va.gov
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in any medium, provided the original work is pto generate health care costs data (Basu et al. 2011). The
data values for patients at the extreme ends of the value
range do not represent the typical experience and can dis-
proportionately influence statistical point estimates. The
lack of symmetry, or skewness that is frequently observed
in medical cost data, is characterized by these extreme
values, known as outliers.
Statistical procedures are useful to identify cases that have
deviated from other cases in the sample, resulting in skew-
ness in large datasets. Some of the statistical techniques are
nonparametric and avoid assumptions that the data are
represented by a particular statistical distribution.
In the medical literature, outliers are often identified by
selecting data on patients with the highest costs based on
statistical trimming rules (Gregori et al. 2009). Researchers
often use cutoff levels ranging from the upper 0.5% to 20%
of the cost distribution, for example. Other approaches in-
clude selecting outliers based on the geometric mean plusan open access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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method (Cots et al. 2003; Pirson et al. 2006). The arithmetic
mean is then calculated based on the data that remain after
the outliers have been trimmed. Disadvantages of these ap-
proaches are that the analysis results are relevant only to
the sample used and the findings cannot be compared to
those of other studies.
In addition to identifying outlying cases in a sample,
investigators frequently identify observations that are in-
fluential. An influential observation is a type of outlying
observation whose exclusion results in major changes in
the fitted regression function or parameters. Usually, ob-
servations exhibiting high leverage (potential to influ-
ence regression results) and large residual (in absolute
value) are influential. Although all influential observa-
tions are outliers, not all outliers are influential
observations.
Standard linear regression models are often used to
predict average costs for patients because these models
are easy to use and their results are easy to interpret.
However, these models are based on the assumption that
the regression errors have a normal distribution and lin-
ear relationships (Paddock et al. 2004; Barber and
Thompson 2004). When these assumptions are violated,
as in data on costs of episodes of care with values that
are markedly different from the rest of the sample, these
models are not appropriate.
Generalized linear models (GLMs) can accommodate
skewness in large datasets by weighting variances (Blough
and Ramsey 2000). Using these models involves specifying
an appropriate model for the mean of the outcome variable
and the correct mean-variance relationship (variance func-
tion) (Mihaylova et al. 2011). Parameters are then estimated
after these structural assumptions are taken into consider-
ation. The mean function estimates from GLMs are gener-
ally robust, and GLMs are less sensitive than linear
regression models to outliers and/or influential observa-
tions. However, mis-specifying the variance function in
GLMs could result in losses of precision. Also, GLMs can
lose efficiency if the data have a large log-scale error vari-
ance or the distribution of errors on the log scale is sym-
metrical but has a heavy tail (Manning and Mullahy 2001;
Mihaylova et al. 2011).
Several statistical techniques can be used to identify and
address outlying and/or influential cases in highly skewed
cost datasets, potentially improving the precision and effi-
ciency of GLMs. Techniques to assess outliers include box-
plot analysis (interquartile method), which involves the use
of distributional characteristics to identify outliers (Pirson
et al. 2006). Winsorization can be used to transform the
costs of outlier episodes so that they are equal to a pre-
established percentile of the data (Thomas and Ward
2006). For example, if the maximum percentile is set at
95% and the minimum at 5%, Winsorization transformscosts for patients with costs above the 95th percentile to the
costs of patients in the 95th percentile and those with costs
in the bottom 5% to the costs of patients in the 5th percent-
ile. Approaches to identify influential observations include
DFBETAs, which are measures of standardized differences
between regression coefficients when a given observation is
included or excluded (Choi 2009). Cook’s distance, another
method for identifying influential observations, summarizes
the influence of each observation on the fitted model pa-
rameters after deleting each observation from the estima-
tion and measuring the resulting aggregate changes in
estimated costs (Indurkhya et al. 2001).
The goal of this study was to demonstrate, by example,
how to identify and handle outliers and how to assess
and handle influential observations by measuring their
magnitude and impact on colon cancer-related costs
(including average episode-based costs and key cost-
drivers). This study also compared the effects of statis-
tical costing methods and approaches for overcoming




We examined data from a retrospective cohort study of
veterans aged 66 years or older with colon cancer who
were enrolled in both the Department of Veterans
Affairs (VA) and Medicare between July 1999 and
December 2001. Data included health care use and cost
data from the VA; Medicare; eight National Cancer In-
stitute Surveillance, Epidemiology, and End Results
(SEER)-affiliated cancer registries; and the VA Central
Cancer Registry. A description of a similar cohort is
available elsewhere (Tarlov et al. 2012). We excluded pa-
tients who had no colon cancer-related costs, were en-
rolled in a Medicare health maintenance organization,
and whose cancer stage at diagnosis was unknown. The
final sample comprised 3,842 elderly veterans with
stages I-IV colon cancer.
The Edward Hines, Jr. VA Hospital institutional review
board (IRB) and the IRBs of the SEER registries ap-
proved the study and waived the requirement for in-
formed consent.
Measures and data sources
We measured colon cancer-related costs in the
12 months following diagnosis and methods are de-
scribed elsewhere (Hynes et al. 2010). In brief, we classi-
fied encounters in Medicare claims and VA records
during this period as colon cancer related if they in-
cluded an International Classification of Diseases, 9th re-
vision, colon cancer diagnosis or colectomy procedure
code; Current Procedural Terminology, 4th edition,
chemotherapy or colectomy procedure code; Medicare
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Pharmacy Benefits Management (PBM) pharmacy class
code for chemotherapy or chemotherapy-related service.
We based costs of services provided through Medicare
on payments in institutional inpatient (Medicare Pro-
vider Analysis and Review file) and outpatient (Out-
patient Standard Analytical File) claims. We also
included allowed charge amounts from non-institutional
provider claims for care provided under Medicare (Car-
rier file). We obtained data on costs of care provided
through the VA from the Health Economic Resource
Center (HERC) Average Cost datasets. HERC estimated
average costs for VA inpatient stays using a Medicare
cost function estimate developed using patient admis-
sion characteristics (Wagner et al. 2003). HERC esti-
mated average costs for VA outpatient visits based on
reimbursement rates from Medicare and other health
care payers and adjusted these payments to reflect the
actual aggregate cost of VA outpatient care (Phibbs et al.
2003). We used VA Fee Basis data (Inpatient, Inpatient
Ancillary, and Outpatient files) to identify costs of cov-
ered care provided to VA patients outside of VA facil-
ities. Our VA pharmacy costs came from PBM data. The
costs we calculated did not include the costs of home
health, long-term care (VA only), or hospice care.
We combined the colon-cancer related health care
costs for VA and Medicare to determine the costs of a
12-month colon cancer episode of care for each patient
in our cohort. We used the Consumer Price Index to ad-
just these costs to 2004 dollars (Bureau of Labor Statitics
and U.S. Department of Labor 2012).
Approaches to identify outliers and influential
observations
We examined four approaches, alone or in combination,
for identifying and assessing or adjusting outliers (box-
plot analysis and Winsorization) and influential observa-
tions (DFBETAs and Cook’s distance) in our full cohort
(Tukey 1962; Barnett and Lewis 1994).
The box-plot (interquartile method) is a graphical ap-
proach that displays the distribution of data and indi-
cates which observations might be outliers (Pirson et al.
2006). We identified observations from the full cohort as
box-plot outliers if ln(cost) > Q3 + 1.5*IQR or ln(cost) <
Q1 – 1.5*IQR, where ln refers to the natural logarithm,
Q3 is the 75th percentile (upper quartile), Q1 is the 25th
percentile (lower quartile), and the interquartile range
(IQR) is Q3 – Q1. We used the natural logarithm trans-
formation because the link function we chose for our
examination of the GLM models was the logarithmic
function.
Winsorization involves replacing (or limiting) extreme
values to reduce the effect of outlying values (Thomas
and Ward 2006). We Winsorized costs at the 2nd and98th percentiles by assigning the cost of the 2nd percent-
ile to observations with costs less than that value and by
assigning costs of the 98th percentile to costs above that
value. In an additional analysis, we Winsorized costs at
the 5th and 95th percentiles.
DFBETAs measure, for each regressor in the model,
the standardized difference between the regression coef-
ficient when the jth observation is included or excluded.
This measurement can be used to determine an observa-
tion’s magnitude of influence on each regression param-
eter estimate. We predicted DFBETA measurements for
each regressor in the model. We identified an observa-
tion as influential if the absolute value of the predicted
DFBETA measurements for stage at diagnosis and colec-
tomy (key cost-driving characteristics) was greater than
the size-adjusted cut-off value of 2/√N or 2/√3,842, or
approximately 0.03 (Belsley et al. 1980). We also used
0.15 as a cut-off value for identifying an observation as
influential because 10–15% change-in-estimate criteria
are frequently used to assess confounding in epidemio-
logical studies (Rothman et al. 2008).
Cook’s distance is a technique to measure the aggre-
gate change in the estimated parameter coefficients
when each observation is omitted from the estimation
and then summarize how each observation influences
the fitted model (Indurkhya et al. 2001). We identified
observations from the full cohort as influential if their
predicted Cook’s distance measurement was greater than
the conventional size-adjusted cut-off value of 4/N or 4/
3,842 (Fox 1991).
We also considered an observation from the full co-
hort to be influential and outlying if the predicted
DFBETA measurement was greater than 0.15 and the
observation was a qualified box-plot outlier.
Identification and comparison of outlying/influential
observations
We calculated the average episode of care cost and dis-
tribution for the full cohort. We then identified outlying
and/or influential observations using box-plot methods,
DFBETAs, and Cook’s distance, and assessed the impact
on our calculations of not including these observations.
We also adjusted cost values for outlying observations
using the Winsorization method. We compared the
average costs of each episode of care to those of the co-
horts we identified using these methods for handling
outliers and influential observations.
Multivariate analysis
We used multivariate GLM models (gamma family
based on modified Park test (Manning and Mullahy
2001) with log link, where ln(E(y|x)) = xβ), to evaluate
the association between select key cost-driving charac-
teristics (stage at diagnosis and colectomy) and 12-





Age at diagnosis 66–75 49.2
76–85 45.8





Marital status Not married 37.7
Married 59.6
Unknown 2.8




Comorbidity scorea,b 0 51.4
1 25.6
2–3 18.5
4 or higher 4.5
Chemotherapyc Yes 33.6
Colectomyd Yes 89.4

























aDeyo-Charlson Comorbidity Index with Romano adaptations.
bMeasured from months −6 to 0 in study period.
cMeasured from months 0 to 12 in study period.
dMeasured from months −1 to 6 in study period.
eMeasured from months −6 to −1 in study period.
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ling for additional factors. We also performed the GLM
modeling using the Poisson and inverse Gaussian fam-
ilies to compare the robustness of our parameter esti-
mates. We calculated estimated expense rate ratios
(ERRs) and 95% confidence intervals (CIs). We then
compared the key cost-driving variable estimates and the
CI widths as a measure of precision from the full cohort
to the estimates we obtained after employing the
approaches for handing outliers and influential observa-
tions described above. Finally, we calculated post-modeling
adjusted cost predictions for the key cost-driving variables
from the full cohort and we compared these to the cost
predictions calculated after we employed the approaches
described above.
We used SAS (version 9.3; SAS Institute, Cary, NC)
and StataW MP software (version 12.1, Stata, College




Among the 3,842 veterans with colon cancer in our co-
hort who were enrolled in both the VA and Medicare
between 1999 and 2001, the average age was 76 years
(standard deviation [SD] = 5.7), 96.5% were male, and
15.5% were African American (Table 1). Of these vet-
erans, 26.8% had Stage I, 30.7% had Stage II, 23.2% had
Stage III, and 19.3% had Stage IV colon cancer. In
addition, 89.4% had undergone cancer-directed colec-
tomy and 33.6% had received chemotherapy within the
12 months following diagnosis. Twenty-three percent
had a modified Deyo-Charlson comorbidity score with
Romano adaptations of 2 or higher (higher scores
indicate a worse baseline health status) (Charlson et al.
1987; Romano et al. 1993; Klabunde et al. 2000;
Klabunde et al. 2006). The average cost of colon cancer
episodes for the cohort was $38,327 (SD = 37,388), with
a range of $43 to $679,472 (Figure 1).
Comparisons after the identification of outlying/
influential observations
The number of observations we identified as outlying
and/or influential varied widely depending on the
method we employed.
The box-plot method identified 227 observations as
outlying (Table 2). Based on their distribution, 45 obser-
vations were upper outlying values and 182 were lower
outlying values. Cases identified as outlying using the
box-plot method had the lowest average cost ($52,952)
of all the methods we used, and the box-plot method
identified the second highest number of outlying cases.
Winsorization at the 2nd and 98th percentiles replaced
152 observations (76 observations in the lower end and76 in the upper end; Table 2). By definition, Winsoriza-
tion at this level replaced 2% of the skewed observations
to the right. This method had a middle average cost
($108,152) for the cases identified compared to the other
Figure 1 Sample size, average cost, and cost distribution for each analytic approach. BP: box-plot.
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replaced 384 observations (192 observations in the lower
end and 192 in the upper end). Winsorization at this
level replaced 5% of the skewed observations to the
right. The average cost ($77,669) of outlying cases was
lower for Winsorization at this level than at the 2nd and
98th percentiles.
The DFBETA method identified 275 observations as
influential at the 0.03 cutoff value and 16 at the 0.15 cut-
off value (Table 2). The 0.03 threshold, as expected,
identified a much larger proportion of influential obser-
vations (more than 15 times as many) as the 0.15 thresh-
old. This method identified observations that were
influential on both the upper and lower ends, as shown
by the lowest cost of all cases identified as influential,
$100. The 0.03 threshold resulted in a lower average cost
($99,398) for cases identified as influential compared to
the other influential observation methods. The average
cost ($265,093) of influential observations identified
using the DFBETA method was higher with a 0.15
threshold than a 0.03 threshold, and the minimum cost
of influential cases identified using the 0.15 threshold
was $50,397.
The Cook’s distance method identified 113 observa-
tions as influential using the specified cut-off value
(Table 2). Among these influential cases, the average
cost ($164,845) was higher than for cases identified with
the box-plot and Winsorization methods. The lowest
cost of all cases identified as influential by the Cook’s
distance method was $33,642.
The method that combined a DFBETA threshold of 0.15
and qualified box-plot outliers identified 13 observations as
influential and outlying. Imposing the additional box-plotoutlier criterion led to the selection of three fewer cases
than the DFBETA method with a 0.15 threshold alone
(Table 2). Compared to the other methods, this combined
method had the highest average cost ($299,690) for cases
identified as influential while identifying the smallest num-
ber of influential cases. In addition, the minimum cost, at
$174,413, was the highest of all the methods we used.
The average 12-month episode of care costs in the co-
horts generated using all of the methods for handling
outliers and influential observations were similar
(Table 3). The average cost for each colon cancer epi-
sode was lowest ($33,619, SD = 22,633, range $43–
$210,530) in the cohort generated using the DFBETA
method with a threshold of 0.03. The average colon can-
cer episode cost was highest, at $37,440 (SD = 33,754;
range $43–$679,472), in the analysis that combined a
DFBETA threshold of 0.15 and qualified box-plot
outliers.
Multivariate analysis comparisons
The GLM regression results using the gamma family
(Figure 2) for the full cohort indicate that costs were
51% higher in patients who underwent colectomy (ERR:
1.51, 95% CI: 1.31–1.73) than in those who did not have
a colectomy. The colectomy ERRs were similar (range
1.37–1.58) after we employed each of the approaches for
handling outliers and influential observations, except for
the box-plot method for defining outliers, which resulted
in an ERR for colectomy of 1.18. The stage at diagnosis
ERRs for the full cohort were of similar magnitude to
those obtained with each of the outlier/influential obser-
vation methods; the estimates from some of the methods
were consistently lower than the estimates from the full
Table 2 Summary of costs for observations identified as outliers and influential observations
BP outliers Winsor02 Winsor05 DFBETA03 DFBETA15 BP/DFBETA15 Cook’s distance
N mean (SD) (range)
Overall
227 152 384 275 16 13 113
52,952 108,152 77,669 99,398 265,093 299,690 164,845
(113,674) (128,017) (94,688) (94,326) (117,330) (98,632) (104,123)
(43–679,472) (43–679,472) (43–679,472) (100–679,472) (50,397–553,115) (174,413–553,115) (33,642–679,472)
Stage at diagnosis
I 135 68 167 114 8 6 39
14,548 49,340 32,973 63,414 230,744 258,473 132,428
(57,758) (90,478) (67,817) (72,948) (69,944) (55,354) (70,472)
(77–358,478) (77–358,478) (77–358,478) (100–358,478) (132,207–358,478) (213,036–358,478) (45,404–358,478)
II 40 40 91 62 3 2 41
112,481 155,546 116,974 136,742 319,201 453,603 172,793
(166,986) (150,250) (110,805) (119,407) (253,169) (140,731) (127,453)
(43–679,472) (43–679,47) (43–679,472) (105–679,472) (50,397–553,115) (354,092–553,115) (33,642–679,472)
III 24 22 64 40 2 2 22
165,703 207,876 134,272 155,595 241,240 241,240 195,733
(131,600) (97,587) (84,274) (90,093) (94,508) (94,508) (98,996)
(120–405,892) (120–405,892) (120–405,892) (53,407–405,892) (174,413–308,068) (174,413–308,068) (61,253–405,892)
IV 28 22 62 59 3 3 11
56,426 104,038 81,940 91,583 318,483 318,483 188,381
(112,415) (119,830) (84,699) (70,256) (60,079) (60,079) (99,654)
(71–362,784) (71–362,784) (71–362,784) (362–362,784) (250,098–362,784) (250,098–362,784) (66,227–362,784)
Colectomy
No 73 27 90 110 4 1 14
5,190 16,293 16,885 34,338 153,281 267,611 100,700
(31,172) (59,158) (45,320) (44,217) (89,802) (−−-) (61,065)
(90–267,611) (90–267,611) (90–267,611) (100–267,611) (50,397–267,611) (267,611–267,611) (33,642–267,611)
Yes 154 125 294 165 12 12 99
75,592 127,993 96,276 142,771 302,364 302,364 173,917
(130,482) (130,341) (98,049) (93,989) (102,525) (102,525) (105,947)
(43–679,472) (43–679,472) (43–679,472) (394–679,472) (174,413–553,115) (174,413–553,115) (45,949–679,472)
BP: box-plot.
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we examined the CIs for each of the key cost-driving
variables, the widths were consistently shortest for the
DFBETA method with a threshold of 0.03 and greatest
for the method that combined a DFBETA threshold of
0.15 and qualified box-plot outliers.
The parameter estimates generated with GLM model-
ing using the Poisson family (results not shown) were
qualitatively similar to the estimates that resulted from
our use of the gamma family GLM (i.e., the stage at
diagnosis and colectomy estimates were in the same dir-
ection after we used each method for identifying outliers
and/or influential observations). The results were alsosimilar quantitatively and of comparable magnitude. All
estimates produced from the Poisson modeling were
closer than the gamma family estimates to the null hy-
pothesis value, except for the DFBETA method with a
threshold of 0.03, which produced estimates for Stage II
and Stage IV colon cancer that were further than the
gamma family estimates to the null hypothesis value.
However, this difference was small.
The results of the GLM modeling using the inverse
Gaussian family (results not shown) were also qualita-
tively similar to the gamma family estimates. The magni-
tude of the estimates was consistently larger for the
inverse Gaussian modeling. All methods for identifying
Table 3 Summary of costs among cohorts identified using methods for handling outliers/influential observations
BP outliers Winsor02 Winsor05 DFBETA03 DFBETA15 BP/DFBETA15 Cook’s distance
N mean (SD) (range)
Overall
3,615 3,842 3,842 3,567 3,826 3,829 3,729
37,409 36,745 35,714 33,619 37,379 37,440 34,493
(25,755) (27,814) (23,763) (22,633) (33,671) (33,754) (24,792)
(5,310–165,803) (693–135,659) (6,255–96,806) (43–210,530) (43–679,472) (43–679,472) (43–228,199)
Stage at diagnosis
I 893 1,028 1,028 914 1,020 1,022 989
29,783 26,796 26,437 23,338 26,190 26,428 23,656
(24,578) (25,489) (21,321) (16,513) (25,192) (25,742) (19,622)
(5,506–165,803) (693–135,659) (6,255–96,806) (77–116,396) (77–242,913) (77–242,913) (77–160,942)
II 1,141 1,181 1,181 1,119 1,178 1,179 1,140
36,547 37,074 35,725 33,710 38,406 38,416 34,312
(25,869) (27,988) (23,505) (22,774) (38,106) (38,092) (24,154)
(6,315–153,706) (693–135,659) (6,255–96,806) (43–210,530) (43–679,472) (43–679,472) (43–210,530)
III 866 890 890 850 888 888 868
43,976 45,170 43,750 42,160 46,821 46,821 43,495
(24,262) (26,889) (22,784) (22,905) (36,306) (36,306) (25,197)
(7,313–164,668) (693–135,659) (6,255–96,806) (120–184,422) (120–405,892) (120–405,892) (120–228,199)
IV 715 743 743 684 740 740 732
40,353 39,897 38,909 36,592 39,834 39,834 38,743
(26,198) (27,589) (24,214) (23,825) (28,470) (28,470) (26,055)
(5,310–150,985) (693–135,659) (6,255–96,806) (71–150,485) (71–237,281) (71–237,281) (71–150,985)
Colectomy
No 334 407 407 297 403 406 393
28,911 24,285 24,531 21,071 23,380 24,058 21,947
(23,990) (24,383) (21,417) (15,166) (22,543) (24,147) (20,392)
(5,310–162,908) (693–135,659) (6,255–96,806) (90–99,518) (90–135,659) (90–162,908) (90–127,699)
Yes 3,281 3,435 3,435 3,270 3,423 3,423 3,336
38,274 38,222 37,040 34,758 39,027 39,027 35,971
(25,775) (27,829) (23,681) (22,855) (34,377) (34,377) (24,849)
(5,506–165,803) (693–135,659) (6,255–96,806) (43–210,530) (43–679,472) (43–679,472) (43–228,199)
BP: box-plot.
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Gaussian modeling were further than the gamma family
estimates from the null hypothesis value, except for the
full sample, box-plot method, and Winsorization at the
5th and 95th percentiles, whose estimates for stage IV
colon cancer were closer than the gamma family esti-
mates to the null hypothesis value. Again, these differ-
ences appeared to be negligible.
Post-modeling predictions revealed that the adjusted costs
for patients grouped by stage at diagnosis and colectomy
status were consistently lower for each of the methods for
identifying outliers and/or influential observations comparedto the full sample. Exceptions were the box-plot method,
which yielded higher predictions for Stage I colon cancer
and patients who did not have a colectomy, and Winsoriza-
tion at the 5th and 95th percentiles, which yielded higher pre-
dictions for patients who did not have a colectomy
(Figure 3). Although the ERR estimates were qualitatively
similar to one another, the adjusted averages varied depend-
ing on the method used. The predicted adjusted average
cost that was closest the majority of the time to that of the
full sample while selecting the smallest amount of cases
came from the method that used a combination of the
DFBETA threshold of 0.15 and qualified box-plot outliers.
Figure 2 Estimated expense rate ratios for key cost-drivers. ERR: expense rate ratio; CI: confidence interval; BP: box-plot.
Weichle et al. SpringerPlus 2013, 2:614 Page 8 of 11
http://www.springerplus.com/content/2/1/614Discussion
In this study, we examined four approaches, alone and
in combination, for addressing outliers and influential
observations in a cohort of 3,842 elderly veterans with
colon cancer. The number of observations we identified
as outlying and/or influential varied widely depending
on the method we employed—from 13 cases when the
predicted DFBETA measurement was greater than 0.15
and the observation was a qualified box-plot outlier to
384 cases when we used the Winsorization method at
the 5th and 95th percentiles. The average cost of outly-
ing/influential observations ranged from $52,952 with
the box-plot method to $299,690 with the combination
of a DFBETA threshold of 0.15 and qualified box-plot
outliers. But in spite of these differences, the average
costs of colon cancer episodes in the cohorts we identi-
fied using all of these methods for handling outliers and
influential observations were similar.
The variations in the numbers of observations identi-
fied as outlying and/or influential by the different
methods we employed can be explained by each
method’s ability to distinguish between different degrees
of skewness to the right. The box-plot method, which
identified slightly more than 1% of the skewness to the
right, might have overemphasized the lower values of
the cost distribution. Similarly, Winsorization might
have placed too much emphasis on the lower percentiles
of the distribution. The fact that the DFBETA method
with the 0.03 threshold resulted in a lower average cost
for cases identified as influential compared to the other
influential observation methods demonstrates that this
method identified more cases on the lower end of the
right skewed distribution. However, the fact that the
average cost ($265,093) of influential observations washigher and the minimum cost was $50,397 with the
DFBETA method and a 0.15 threshold demonstrates that
more cases were removed to the right of the population
average and that this method selects high leverage values
with large residual error. The minimum cost of all cases
identified as influential by Cook’s distance, at $33,642,
shows that the Cook’s distance method identifies the lar-
ger costs of a right skewed cost distribution. Using the
method that combined a DFBETA threshold of 0.15 and
qualified box-plot outliers resulted in the highest average
cost ($299,690) for cases identified as influential, the
smallest number of influential cases, and the highest
minimum cost for influential cases of all the methods we
used. This method targets those observations that are
skewed to the right and has a greater than 15% change
on the parameter estimate.
All of the methods for handling outliers and influential
observations appeared to yield similar results with re-
gard to the average cost estimates. The number of cases
that we identified as influential was highest when we
used the DFBETA method with a threshold of 0.03,
which explains why the calculated mean cost was lowest
using the cases in this cohort that we identified. The
average colon cancer episode cost was highest, at
$37,440 (SD = 33,754; range $43–$679,472), in the ana-
lysis that used the combination of a DFBETA threshold
of 0.15 and qualified box-plot outliers is due to the fact
that the method identified the smallest number of cases.
Although these cases were highly influential and outly-
ing, their number was too small to induce a major
change in the cost of the average colon cancer episode.
The colectomy ERRs were similar (range 1.37–1.58)
after we employed each of the approaches for handling
outliers and influential observations, except for the box-
Figure 3 Estimated Post-Modeling Cost Predictions for Key Cost-Drivers. CI: confidence interval; BP: box-plot.
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ERR of 1.18. The identification and handling of cases on
both the lower and upper ends of the distribution in the
box-plot method greatly reduced the margin of differ-
ence in cost between the colectomy and no-colectomy
cases.
The ERR estimates for stage at diagnosis were consist-
ently lower for the box-plot and Winsorization methods
than the ERR estimates for the full cohort. The upper
outlying cost values from the cohort identified using the
box-plot method had a larger impact on the regression
estimates than the lower outlying values because the es-
timates for each cancer stage were consistently lower
than the estimates for each stage in the full cohort even
though the box-plot method identified more lower out-
lying values than higher outlying values. If the patients
with the highest costs in our original cohort tended to
have Stage III or Stage IV colon cancer, the Winsoriza-
tion processes were most likely to adjust for these higher
costs. As a result, Winsorization consistently yielded
stage estimates that were lower than for the full cohort.
Winsorization at the 5th and 95th percentiles resulted
in estimates that were lower than Winsorization at the
2nd and 98th percentiles. One likely reason for this was
that the method adjusted the higher costs associated
with advanced-stage cases to a smaller value (the value
of cases at the 95th percentile) than the costs of cases in
the 98th percentile, and the costs of Stage I cases, which
were lower than the costs of more advanced-stage cases,
were adjusted to the cost of cases in the 5th percentile,
which was higher than the costs of cases in the 2ndpercentile. When we compared the regression estimates
of the full sample to the estimates from the box-plot and
Winsorization methods, reductions in estimates were
generally greater for patients with more advanced-stage
cancer because these cases were more likely to be identi-
fied as cost outliers.
The regression estimates for stage at diagnosis were
consistently higher for the two methods that identified
influential costs—DFBETA and Cook’s distance—than
for the full cohort. Thus, it is possible that the DFBETA
and Cook’s distance methods identified many cases with
low or middle costs that were influential in addition to
some influential high-cost records, which would increase
the regression estimates and gradually increase esti-
mated costs from lower-stage to higher-stage colon
cancer.
The method that combined the DFBETA threshold of
0.15 and qualified box-plot outliers produced regression
estimates that were very similar to those of the full co-
hort. A possible explanation might be that, at only 13,
the number and value of influential observations we
identified using the combined criteria was too small to
induce a large change in the model. This method is ro-
bust as it uses a combination of outlying and influential
criteria and yields results that are consistent with the re-
gression estimates for the full cohort.
We observed that the CI widths were consistently
shortest for the DFBETA method with a threshold of
0.03. Even though this method identified the largest
number of influential observations, the widths were al-
most half of the distance compared to the full cohort,
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provement in precision. In contrast, the widths were
greatest for the method that combined a DFBETA
threshold of 0.15 and qualified box-plot outliers. This
method identified the smallest number of influential ob-
servations, and although it was robust in its targeting of
outlying and influential observations, precision was the
lowest of all methods.
The similarity of the regression estimates comparing
the GLM models using the gamma family to the Poisson
and inverse Gaussian families (results not shown) sug-
gested robustness of GLMs in addressing skewness in
large datasets. Although we observed this similarity in
our data, this might not be the case in all circumstances
and careful consideration should be given to successfully
specifying the variance function (Manning and Mullahy
2001; Mihaylova et al. 2011).
This study showed that although each of the methods
we used identified different numbers of cases as outliers
and/or influential observations, these methods produced
generally similar overall average costs and average costs
by stage at diagnosis and colectomy receipt. Further-
more, the ERRs of the key cost-drivers produced from
the GLM modeling were quantitatively and qualitatively
similar and of comparable magnitude. However, our
post-modeling predictions of average costs for stage at
diagnosis and colectomy receipt varied slightly depend-
ing on the method we used.
This study compared the effects of using alternative
approaches to identifying outlying and influential obser-
vations on costs of colon cancer episodes of care. Under-
standing how estimates could change with each
approach is important in determining whether to use a
particular method. We used rule-of-thumb cut-off values
to identify observations as outlying or influential that
are, to some extent, arbitrary, and our findings might
have been different if we had used different cut-off
values. These remedial measures for handling outliers
and influential observations should be employed if the
fitted model leads to major changes in the inferences
drawn when cases are omitted (Kutner et al. 2004).
Conclusions
Although we do not recommend any single method for
all analyses, we believe that based on the results of this
study, the method of choice can be conditionally based
on the analytic purpose. If the purpose is to control only
for influential observations, then the method of choice is
the DFBETA method with a threshold of 0.03 because it
produced estimates of similar magnitude to those pro-
duced using the full cohort while demonstrating the
most improvement in precision as CI widths were con-
sistently shortest. If the purpose is to simultaneously
control for outliers and influential observations, then themethod of choice is the one that identifies outliers and
influential observations using the combination of a
DFBETA threshold of 0.15 and qualified box-plot out-
liers because this method targets those observations that
are skewed to the right and has a substantial influence
on the parameter estimate. This method produced the
closest average colon cancer episode cost and similar re-
gression estimates to those of the full cohort but did so
at the expense of precision. The analysis of skewed data
should always consider different options for handling
outlying and influential cases. Although the conditional
methods of choice were applied to cost data in this case,
the methods could be appropriate for other data with
right skewness as well and the analyst should select an
approach for handling outliers and influential observa-
tions based on the specific data structure and subject
matter knowledge.
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